Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Phase 3 Completed 234 enrolled BioCryst Pharmaceuticals Department of Health and Human Services · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.

Timeline

Start: 2009-10
Primary completion: 2010-10
Completion: 2011-08

Publications

Ison MG, Fraiz J, Heller B, Jauregui L, Mills G, O'Riordan W, O'Neil B, Playford EG, Rolf JD, Sada-Diaz E, Elder J, Collis P, Hernandez JE, Sheridan WP. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349-61. doi: 10.3851/IMP2680. Epub 2013 Aug 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PERAMIVIR ANHYDROUS	Small molecule	300 mg	Intravenous
Subject	PERAMIVIR ANHYDROUS	Small molecule	600 mg	Intravenous

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Summary

Timeline

Publications

Drugs

Indications